Key points are not available for this paper at this time.
patients starting second line drug treatment who require faster correction of their anaemia than would be achieved by the modifying effect on the disease of such drugs.We thank Cilag for providing the human recombinant erythropoietin and matching placebo; metrologists Anne Thomson (Glasgow), Frances McEvoy (Belfast), and Gwynneth Clarke (Eastbourne); Dorothy McKnight for help with computing; and Professor R D Sturrock and Drs A Zoma and Max Field for allowing us to include their patients in the study.
Harvey et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: